Impact of dipeptidyl peptidase-4 inhibitors on malignant tumours among type 2 diabetes: a network meta-analysis




Poster session 1


Monday 24 October 2016 - 10:30 to 11:00


All authors in correct order:

Yang X1, Shanshan W2, Jun Y1, Ting C1, Siyan Z1, Feng S1
1 Department of Epidemiology and Biostatistics, School of Public Health, Peking University, China
2 National Clinical Research Center of Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China
Presenting author and contact person

Presenting author:

Xu Yang

Contact person:

Abstract text
Background: Dipeptidyl peptidase-4 inhibitors (DPP-4Is) are increasingly used in patients with type 2 diabetes (T2DM). However, the effects of DPP-4s on malignant tumours have not been confirmed.

Objectives: To review systematically the effects of DPP-4Is on malignant tumours in patients with T2DM.

Methods: The Cochrane Library, Embase, MEDLINE and Clinical Trials were searched from inception through to November 2015 to identify randomized controlled trials (RCTs) that assessed the safety of DPP-4Is versus placebo or other anti-diabetic drugs in T2DM. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated through network meta-analysis.

Results: Sixty RCTs were included, which included 14 treatments: six DPP-4Is (alogliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin, vildagliptin), two glucagon-like peptide-1 (GLP-1s) (dulaglutide, exenatide), two sodium/glucose cotransporter 2 (SGLT-2s) (canagliflozin, empagliflozin), placebo and three traditional anti-diabetic drugs. Although there were no statistically significant increases in effects on malignant tumours when DPP-4Is were compared with GLP-1s, SGLT-2s, sulfonylureas, biguanides, or thiazolidinediones, there is a trend for increasing of malignant tumours when DPP-4Is versus GLP-1s, sulfonylureas, and thiazolidinediones (with a range of ORs: 1.14 (95% CI 0.50 to 2.32), 1.17 (95% CI 0.81 to 1.88), 1.49 (95% CI 0.34 to 9.89)).

Conclusions: There is no evidence that DPP-4Is were associated with increasing effect on malignant tumours. Studies with more patients and longer durations of follow-up need to be done to identify the relationship between DPP-4Is and malignant tumours.

PROSPERO register: CRD42015020401